Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 13;19(12):7247.
doi: 10.3390/ijerph19127247.

Prevalence of Patients Receiving Urate-Lowering Medicine in Greenland and Denmark: A Cross-Sectional Case-Control Study

Sidsel Dan Hull  1 , Marianne Welzel Andersen  2 , Jessica Bengtsson  1 , Nils Skovgaard  2 , Marie Balslev Backe  3   4 , Michael Lynge Pedersen  3   4
Affiliations

Prevalence of Patients Receiving Urate-Lowering Medicine in Greenland and Denmark: A Cross-Sectional Case-Control Study

Sidsel Dan Hull et al. Int J Environ Res Public Health. .

Abstract

This study estimates the age- and sex-specific prevalence of patients receiving urate-lowering therapy (ULT) in Greenland and compares the results with estimates in Denmark. Characteristics of patients receiving ULT in Greenland were compared to age- and sex-matched controls. The study was designed as a cross-sectional case−control study based on nationwide data from medical and population registers in Greenland and Denmark. The prevalence of patients receiving ULT was significantly lower in Greenland (0.55%) compared to Denmark (1.40%) (p < 0.001). In both countries, the prevalence increased with age and was higher among men compared to women. In Greenland, patients receiving ULT were more often overweight, and more frequently received blood glucose-, lipid-, and blood pressure-lowering medicine including diuretics compared to age- and sex-matched controls. The prevalence of patients receiving ULT was significantly lower in Greenland compared to Denmark. Common life-style related risk factors for hyperuricemia and gout were observed frequently among ULT-treated patients compared to controls. Along with an increasing prevalence of lifestyle-related diseases in Greenland, the prevalence of patients receiving ULT may increase in the years to come. More focus on detection and management of hyperuricemia and gout in Greenland is warranted to improve quality of health care.

Keywords: Denmark; Greenland; allopurinol; febuxostat; gout; prevalence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Richette P., Doherty M., Pascual E., Barskova V., Becce F., Castañeda-Sanabria J., Coyfish M., Guillo S., Jansen T.L., Janssens H., et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 2017;76:29–42. doi: 10.1136/annrheumdis-2016-209707. - DOI - PubMed
    1. Sampson A.L., Singer R.F., Walters G.D. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Kidney and Transplant Group, editor. Cochrane Database Syst. Rev. 2017;10:CD009460. doi: 10.1002/14651858.CD009460.pub2. - DOI - PMC - PubMed
    1. Dehlin M., Jacobsson L., Roddy E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors. Nat. Rev. Rheumatol. 2020;16:380–390. doi: 10.1038/s41584-020-0441-1. - DOI - PubMed
    1. Richette P., Doherty M., Pascual E., Barskova V., Becce F., Castaneda J., Coyfish M., Guillo S., Jansen T., Janssens H., et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann. Rheum. Dis. 2020;79:31–38. doi: 10.1136/annrheumdis-2019-215315. - DOI - PubMed
    1. Backe M.B., Pedersen M.L. Prevalence, incidence, mortality, and quality of care of diagnosed diabetes in Greenland. Diabetes Res. Clin. Pract. 2020;160:107991. doi: 10.1016/j.diabres.2019.107991. - DOI - PubMed

Publication types